Skip to main content
Year archive

Strategic Partners A/S — 2019 filings

All 42 regulatory filings released by Strategic Partners A/S (STRAP) in 2019, sourced directly from the official regulator.

42 Filings
2019 Period
2019 filings (42)
Filing Released Lang
Major shareholder announcement
Major Shareholding Notification
2019-12-19 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-12-19 English
Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
Regulatory Filings
2019-12-18 English
Regulatory Filings 2019
Regulatory Filings
2019-12-18 English
Major shareholder announcement
Major Shareholding Notification
2019-11-28 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-11-28 English
Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
Regulatory Filings
2019-11-19 English
Regulatory Filings 2019
Regulatory Filings
2019-11-19 English
Major shareholder announcement
Major Shareholding Notification
2019-10-02 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-10-02 English
Orphazyme announces Interim Report First Half 2019
Interim / Quarterly Report H1 2019
2019-08-28 English
Orphazyme announces Interim Report First Half 2019
Report Publication Announcement H1 2019
2019-08-28 English
Report Publication Announcement 2019
Report Publication Announcement H1 2019
2019-08-28 English
Orphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital
Capital/Financing Update
2019-08-27 English
Capital/Financing Update 2019
Capital/Financing Update
2019-08-27 English
Major shareholder announcement
Major Shareholding Notification
2019-08-05 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-08-05 English
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
Regulatory Filings
2019-07-21 English
Regulatory Filings 2019
Regulatory Filings
2019-07-21 English
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
Regulatory Filings
2019-07-18 English
Regulatory Filings 2019
Regulatory Filings
2019-07-18 English
Orphazyme appoints Kim Stratton as Chief Executive Officer
Board/Management Information
2019-07-15 English
Board/Management Information 2019
Board/Management Information
2019-07-15 English
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
Regulatory Filings
2019-06-07 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-06-07 English
Major shareholder announcement
Major Shareholding Notification
2019-05-31 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-05-31 English
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Regulatory Filings
2019-04-23 English
Regulatory Filings 2019
Regulatory Filings
2019-04-23 English
Major shareholder announcement
Major Shareholding Notification
2019-04-17 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-04-17 English
Share capital and voting rights in Orphazyme A/S
Share Issue/Capital Change
2019-03-29 English
Share capital and voting rights in Orphazyme A/S
Share Issue/Capital Change
2019-03-29 English
Report Publication Announcement 2019
Report Publication Announcement
2019-03-01 English
Orphazyme announces Annual Report 2018
Annual Report FY 2018
2019-03-01 English
Orphazyme announces Annual Report 2018
Report Publication Announcement
2019-03-01 English
Capital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change
2019-01-31 English
Capital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change
2019-01-31 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-30 English
Major shareholder announcement
Major Shareholding Notification
2019-01-30 English
Regulatory Filings 2019
Regulatory Filings
2019-01-30 English
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
Earnings Release Q1 2019
2019-01-30 English